Plasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System
2020; Lippincott Williams & Wilkins; Volume: 76; Issue: 5 Linguagem: Inglês
10.1161/hypertensionaha.120.15841
ISSN1524-4563
AutoresUlrich Kintscher, Anna Slagman, Oliver Domenig, Robert Röhle, Frank Konietschke, Marko Poglitsch, Martin Möckel,
Tópico(s)Long-Term Effects of COVID-19
ResumoHomeHypertensionVol. 76, No. 5Plasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBPlasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System Ulrich Kintscher, Anna Slagman, Oliver Domenig, Robert Röhle, Frank Konietschke, Marko Poglitsch and Martin Möckel Ulrich KintscherUlrich Kintscher Correspondence to Ulrich Kintscher, Charité–Universitätsmedizin Berlin, Institute of Pharmacology, Center for Cardiovascular Research, Hessische Strasse 3-4, 10115 Berlin, Germany. Email E-mail Address: [email protected] https://orcid.org/0000-0001-7386-0990 From the Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (U.K., A.S., M.M., R.R., F.K.) Institute of Pharmacology, Center for Cardiovascular Research, Germany (U.K.) DZHK (German Centre for Cardiovascular Research), Partner Site Berlin (U.K.) , Anna SlagmanAnna Slagman From the Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (U.K., A.S., M.M., R.R., F.K.) Department of Emergency and Acute Medicine, Campus Mitte and Campus Virchow Clinic (A.S., M.M.) , Oliver DomenigOliver Domenig Attoquant Diagnostics, Vienna, Austria (O.D., M.P.). , Robert RöhleRobert Röhle https://orcid.org/0000-0002-8130-6524 From the Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (U.K., A.S., M.M., R.R., F.K.) Institute of Biometry and Clinical Epidemiology, Coordinating Center for Clinical Studies (R.R.) Berlin Institute of Health, Germany (R.R., F.K.) , Frank KonietschkeFrank Konietschke From the Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (U.K., A.S., M.M., R.R., F.K.) Institute of Biometry and Clinical Epidemiology (F.K.) Berlin Institute of Health, Germany (R.R., F.K.) , Marko PoglitschMarko Poglitsch Attoquant Diagnostics, Vienna, Austria (O.D., M.P.). and Martin MöckelMartin Möckel https://orcid.org/0000-0002-7691-3709 From the Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (U.K., A.S., M.M., R.R., F.K.) Department of Emergency and Acute Medicine, Campus Mitte and Campus Virchow Clinic (A.S., M.M.) Originally published27 Aug 2020https://doi.org/10.1161/HYPERTENSIONAHA.120.15841Hypertension. 2020;76:e34–e36Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: August 27, 2020: Ahead of Print Pharmacological blockade of the renin-angiotensin system (RAS) with ACE (angiotensin-converting enzyme) inhibitors or angiotensin type 1 receptor blockers (ARB) reduces morbidity and mortality in various cardiovascular diseases. One of the key RAS-modulating enzymes, ACE2, has recently gained increasing attention because it converts not only angiotensin (Ang) II to the alternative RAS metabolite Ang-(1–7) but also functions as the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2.1 At the beginning of the SARS-CoV-2 pandemic, some investigators suggested that because ACE inhibitor or ARB may lead to upregulation of ACE2 expression/activity, use of these agents in coronavirus disease 2019 (COVID-19) patients might be associated with worsened outcomes.1 Meanwhile, several observational studies have shown that neither the risk of COVID-19 nor its severity is negatively affected by ACE inhibitor or ARB.2,3 However, it remains unclear how RAS activity, particularly ACE2, is regulated in COVID-19 and how this is altered by ACE inhibitor/ARB therapy. In this study, we analyzed distinct RAS components in plasma from patients with COVID-19 ±ACE inhibitor/ARB therapy using liquid chromatography-mass spectrometry/mass spectrometry.The study was approved by the Charité-Universitäts-medizin, Berlin, Germany, Institutional Ethics Committee (EA2/204/19, Amendment 1) and registered in the German Registry for Clinical Studies (DRKS00019207). Surplus plasma samples were collected at the time of admission to the emergency room from 6 different patient groups (total, n=58 [women, 21]): SARS-CoV-2 negative control group (control, n=9 [4]), SARS-CoV-2 negative with ACE inhibitor (control-ACE inhibitor, n=10 [2]), SARS-CoV-2 negative with ARBs (control-ARB, n=8 [5]), COVID-19 without ACE inhibitor/ARB (COVID, n=12 [5]), COVID-19 with ACE inhibitor (COVID-ACE inhibitor, n=10 [2]), and COVID-19 with ARBs (COVID-ARB, n=9 [3]). Equilibrium levels of Ang-peptides (Ang I, Ang II, Ang-[1–7], and Ang-[1–5]) were measured using liquid chromatography-mass spectrometry/mass spectrometry technology (Attoquant Diagnostics).4 Ang-based markers for ACE (Ang II/Ang I) and plasma renin activity (Ang I+Ang II) were calculated from Ang-peptide levels. ACE2 activity was assayed by a classical kinetic approach applying its natural substrate (ex vivo spiked Ang II) and measuring the turnover to Ang-(1–7)±ACE2 inhibitor MLN-4760. The inhibitor-sensitive ACE2-specific turnover was converted to an ACE2 concentration using a calibration curve of recombinant human ACE2. Ang-peptide concentrations/ratios, ACE2 activity, and age between groups were compared using the Kruskal-Wallis test. In case of a significant result, the Dunn-Test for pairwise comparisons using Bonferroni correction was applied. A P of <0.05 was considered statistically significant, although results have to be considered exploratory.Patient CharacteristicsAge (years, mean±SD): control, 44.8±19.7; control-ACE inhibitor, 63.6±17.8; control-ARB, 73.1±11.4 (P=0.02 versus control); COVID, 50±15.1; COVID-ACE inhibitor, 61.4±20.9; COVID-ARB, 74.2±10.1 (P=0.02 versus COVID); COVID severity (n/group), as defined previously,3 severe (intensive care unit admission, mechanical ventilation, and death): COVID (2), COVID-ACE inhibitor (1), COVID-ARB (1); acute renal failure ([n/group] control-ARB [2], COVID [1], COVID-ARB [1]); diuretic use (n/group): control (0), control-ACE inhibitor (4), control-ARB (6), COVID (0), COVID-ACE inhibitor (1), and COVID-ARB (3). Coexisting conditions are outlined in the Figure (A).ResultsAng-peptide equilibrium concentrations did not significantly differ between the control and COVID groups without ACE inhibitor/ARB treatment (Figure [B], left). More importantly, Ang I+II, Ang II/Ang I, and ACE2 activity were not significantly different between both groups (Figure [C]). These data suggest that patients with COVID-19 are not those with increased RAS activity levels and that particularly COVID-19–induced alternative RAS activation, potentially mediated through circulating ACE2, is not a typical feature in our patient cohort.Download figureDownload PowerPointFigure. Patient characteristics, Ang (angiotensin) peptide profiles, and ACE (angiotensin-converting enzyme)-2 levels. A, The presence of cardiovascular disease (hypertension, coronary artery disease, and chronic heart failure) and type 2 diabetes mellitus depicted as percentage of patients in each group. B, Plasma Ang-peptide concentrations and renin-angiotensin system (RAS) enzymatic cascade are depicted as RAS Fingerprints. The concentration of indicated Ang metabolites is reflected by the size of the corresponding sphere. Blue arrows indicate enzymes that are known to carry out metabolic conversions between connected Ang metabolites. Numbers represent median concentrations (pmol/L) and interquartile ranges in parentheses. C, Ang-based markers for plasma renin activity: Ang I+Ang II and ACE: Ang II/Ang I were calculated from Ang-peptide levels. ACE2 activity was measured as described above. Data are shown as dot plots and median. Significant P values within each group (control and coronavirus disease 2019 [COVID]) are indicated. control: severe acute respiratory syndrome coronavirus 2 negative control group without ACE inhibitor/angiotensin type 1 receptor blocker (ARB) therapy; control+ACE inhibitor: severe acute respiratory syndrome coronavirus 2 negative control group with ACE inhibitor therapy; control+ARB: severe acute respiratory syndrome coronavirus 2 negative control group with ARB therapy; COVID: patients with COVID-19 without ACE inhibitor/ARB; COVID+ACE inhibitor: patients with COVID-19 with ACE inhibitor therapy; COVID+ARB: patients with COVID-19 with ARB therapy. ACEi indicates ACE inhibitor; and CTRL, control.Comparison of all groups, including ACE inhibitor/ARB treatment groups, revealed no significant differences of Ang I+II levels between the groups (Figure [C], upper left). Ang I+II is a reliable marker for plasma renin activity and did not change significantly, despite the use of ACE inhibitor/ARB, while median values were clearly increased in patients on ACE inhibitor/ARB. This is consistent with previous observations demonstrating a broad spectrum of intensity in compensatory renin secretion in patients treated with ACE inhibitor or ARB.4 As expected, patients in the control-ACE inhibitor and COVID-ACE inhibitor group showed increased Ang I and markedly suppressed Ang II levels (Figure [B]), resulting in a significant reduction of the Ang II/Ang I ratio (Figure [C], lower left). Ang-(1–5) levels did not significantly differ between groups, whereas Ang-(1–7) was significantly increased in the COVID-ACE inhibitor group versus COVID without ACE inhibitor/ARB (P=0.01) and versus COVID-ARB (P=0.045). ACE2 activity was significantly higher in patients with COVID-19 treated with ACE inhibitor compared with patients with COVID-19 without ACE inhibitor/ARB (Figure [C], right). ACE2 activity was also increased in the control-ACE inhibitor and control-ARB group but did not reach statistical significance (Figure [C], right). ARB treatment in COVID-19 did not significantly affect ACE2 activity (Figure [C], right).The main findings of this study are as follows: (1) patients with COVID-19 are not characterized by major changes in RAS activity in plasma including ACE2 activity, (2) ACE inhibitor therapy significantly suppressed Ang II/Ang I ratios, the Ang-based marker for ACE, in COVID-19 and in non–patients with COVID-19, and (3) plasma ACE2 activity is increased in patients with COVID-19 treated with ACE inhibitor. These data are consistent with previously published results in SARS-CoV-2–negative patients treated with ACE inhibitor or ARB demonstrating an Ang II/Ang I suppression and a more profound increase of Ang-(1–7) under ACE inhibitor compared with ARBs.4 The data published so far on plasma ACE2 activity and Ang-(1–7) levels in patients without COVID treated with ACE inhibitor or ARBs are controversial.1 Some studies showed an increase in circulating ACE2 activity and Ang-(1–7) levels that cannot be proven by other studies.1 In addition, increased ACE2 activity has been identified in multiple cardiovascular diseases such as hypertension, coronary artery disease, and chronic heart failure, which are usually treated with ACE inhibitor.1 Whether the ACE inhibitor treatment in our study plays a role in ACE2 upregulation or whether these changes are mediated by the increased presence of cardiovascular disease in this group requires further investigation. Furthermore, the clinical significance of the elevated ACE2 activity in patients with COVID-19 treated with ACE inhibitor is currently not completely understood. Whether plasma ACE2 level may be a reliable marker of the full-length membrane bound form1 and whether ACE2 serves as a marker for disease severity or endothelial regeneration in the lung5 need to be clarified in future studies. Some of the major limitations of this study include small sample sizes, lack of a power analysis, lack of any data on blood pressure when the plasma samples were obtained, and lack of any data on duration of illness. Finally, it should be emphasized that the majority of the study patients were not experiencing severe COVID-19. However, we provide for the first time a snapshot of distinct systemic RAS components in patients with COVID-19 under ACE inhibitor/ARB therapy that helps to understand the clinical data on a molecular pharmacological level.AcknowledgmentsWe thank Fabian Holert, Jana Eberst, and Beata Hoeft for the support with sample preparation/handling and clinical data collection.Sources of FundingThis study was supported by institutional funding from the Charité–Universitätsmedizin Berlin, Germany. U. Kintscher is supported by the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research); BER 5.4 PR, the Deutsche Forschungsgemeinschaft (KI 712/10-1), the BMBF/BfR1328-564 m, and the Einstein Foundation/Foundation Charité (EVF-BIH-2018-440).DisclosuresO. Domenig and M. Poglitsch are employees of Attoquant Diagnostics, Vienna, Austria. U. Kintscher received research grants/speaker honoraria from Bayer. U. Kintscher received speaker honoraria from Berlin Chemie, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Sanofi, and Servier and participated in advisory boards of Berlin Chemie, Boehringer Ingelheim, Novartis, and Sanofi. M. Möckel received research grants/speaker honoraria from Roche Diagnostics and BRAHMS ThermoFisher; M. Möckel received speaker honoraria from Boehringer Ingelheim, Daiichi Sankyo, Novartis, and Bristol Myers Squibb and participated in advisory boards of Daiichi Sankyo and Boehringer Ingelheim. The other authors report no conflicts.FootnotesCorrespondence to Ulrich Kintscher, Charité–Universitätsmedizin Berlin, Institute of Pharmacology, Center for Cardiovascular Research, Hessische Strasse 3-4, 10115 Berlin, Germany. Email ulrich.kintscher@charite.deReferences1. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19.N Engl J Med. 2020; 382:1653–1659. doi: 10.1056/NEJMsr2005760CrossrefMedlineGoogle Scholar2. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19.N Engl J Med. 2020; 382:2431–2440. doi: 10.1056/NEJMoa2006923CrossrefMedlineGoogle Scholar3. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19.N Engl J Med. 2020; 382:2441–2448. doi: 10.1056/NEJMoa2008975CrossrefMedlineGoogle Scholar4. Binder C, Poglitsch M, Agibetov A, Duca F, Zotter-Tufaro C, Nitsche C, Aschauer S, Kammerlander AA, Oeztuerk B, Hengstenberg C, et al. Angs (angiotensins) of the alternative renin-angiotensin system predict outcome in patients with heart failure and preserved ejection fraction.Hypertension. 2019; 74:285–294. doi: 10.1161/HYPERTENSIONAHA.119.12786LinkGoogle Scholar5. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19.N Engl J Med. 2020; 383:120–128. doi: 10.1056/NEJMoa2015432CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Sütő R, Pócsi M, Fagyas M, Kalina E, Fejes Z, Szentkereszty Z, Kappelmayer J and Nagy Jr. B (2024) Comparison of Different Vascular Biomarkers for Predicting In-Hospital Mortality in Severe SARS-CoV-2 Infection, Microorganisms, 10.3390/microorganisms12010229, 12:1, (229) Ahiadu B, Grunbaum A, Rozza N, Kremer R and Rusling J (2023) Levels of Angiotensin and Kinin Metabolite Peptides Related to COVID-19 Severity, ACS Pharmacology & Translational Science, 10.1021/acsptsci.3c00227, 7:1, (186-194), Online publication date: 12-Jan-2024. Mohammed Y, Tran K, Carlsten C, Ryerson C, Wong A, Lee T, Cheng M, Vinh D, Lee T, Winston B, Sweet D, Boyd J, Walley K, Haljan G, McGeer A, Lamontagne F, Fowler R, Maslove D, Singer J, Patrick D, Marshall J, Murthy S, Jain F, Borchers C, Goodlett D, Levin A and Russell J (2023) Proteomic Evolution from Acute to Post-COVID-19 Conditions, Journal of Proteome Research, 10.1021/acs.jproteome.3c00324, 23:1, (52-70), Online publication date: 5-Jan-2024. O'Keeffe M, Oterhals Å, Vikøren L, Drotningsvik A, Mellgren G, Halstensen A and Gudbrandsen O (2023) Dietary fish intake increased the concentration of soluble ACE2 in rats: can fish consumption reduce the risk of COVID-19 infection through interception of SARS-CoV-2 by soluble ACE2?, British Journal of Nutrition, 10.1017/S0007114523000776, 130:10, (1712-1719), Online publication date: 28-Nov-2023. Ahiadu B, Ellis T, Graichen A, Kremer R and Rusling J (2023) Quantitative detection of RAS and KKS peptides in COVID-19 patient serum by stable isotope dimethyl labeling LC-MS, The Analyst, 10.1039/D3AN00943B, 148:23, (5926-5934) Rathkolb V, Traugott M, Heinzel A, Poglitsch M, Aberle J, Eskandary F, Abrahamowicz A, Mueller M, Knollmueller P, Shoumariyeh T, Stuflesser J, Seeber I, Gibas G, Mayfurth H, Tinhof V, Schmoelz L, Zeitlinger M, Schoergenhofer C, Jilma B, Genser B, Hoepler W, Omid S, Karolyi M, Wenisch C, Oberbauer R, Zoufaly A, Hecking M and Reindl-Schwaighofer R (2023) Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial, iScience, 10.1016/j.isci.2023.108146, 26:11, (108146), Online publication date: 1-Nov-2023. Ames M, Adin D and Wood J (2023) Beyond Angiotensin-Converting Enzyme Inhibitors, Veterinary Clinics of North America: Small Animal Practice, 10.1016/j.cvsm.2023.05.015, 53:6, (1353-1366), Online publication date: 1-Nov-2023. Brethel S, Locker S, Girens R, Rivera P, Meurs K and Adin D (2023) The effect of taurine supplementation on the renin–angiotensin–aldosterone system of dogs with congestive heart failure, Scientific Reports, 10.1038/s41598-023-37978-1, 13:1 Adin D, Spalla M, Walden H, Gruntmeir J, Hernandez J and Long M (2023) Angiotensin-converting enzyme 2 in dogs with Dirofilaria immitis, Parasites & Vectors, 10.1186/s13071-023-05649-9, 16:1 Chen H, Peng J, Wang T, Wen J, Chen S, Huang Y and Zhang Y (2023) Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic, Biochemical Pharmacology, 10.1016/j.bcp.2022.115370, 208, (115370), Online publication date: 1-Feb-2023. Burkhardt A, Lu A, Asante I and Louie S (2023) Pharmacologic Therapeutics for COVID‐19 Coronavirus Disease 2019 (COVID‐19), 10.1002/9781119789741.ch13, (290-318), Online publication date: 6-Jan-2023. Naderi N and Rahimzadeh M The Role of Soluble ACE2 as a Prognostic Marker in Severe COVID-19: A Brief Meta-Analysis, Endocrine, Metabolic & Immune Disorders - Drug Targets, 10.2174/1871530322666220623121922, 23:1, (70-76) Adin D and Hernandez J (2022) Influence of sex on renin‐angiotensin‐aldosterone system metabolites and enzymes in Doberman Pinschers, Journal of Veterinary Internal Medicine, 10.1111/jvim.16589, 37:1, (22-27), Online publication date: 1-Jan-2023. Ozkan S and Ipekci A (2023) Serum Angiotensin II as a Biomarker in COVID-19 Biomarkers in Trauma, Injury and Critical Care, 10.1007/978-3-031-07395-3_69, (917-940), . Robertson J, Nellgård B, Hultén L, Nilsson S, Dalla K, Börjesson M, Zetterberg H, Svanvik J and Gisslén M (2022) Sex difference in circulating soluble form of ACE2 protein in moderate and severe COVID-19 and healthy controls, Frontiers in Medicine, 10.3389/fmed.2022.1058120, 9 Devaux C and Camoin-Jau L (2022) An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection, Frontiers in Microbiology, 10.3389/fmicb.2022.1042200, 13 Reindl-Schwaighofer R, Hödlmoser S, Domenig O, Krenn K, Eskandary F, Krenn S, Schörgenhofer C, Rumpf B, Karolyi M, Traugott M, Abrahamowicz A, Tinhof V, Mayfurth H, Rathkolb V, Mußnig S, Schmölz L, Ullrich R, Heinzel A, König F, Binder C, Bonderman D, Strassl R, Puchhammer-Stöckl E, Gorkiewicz G, Aberle J, Jilma B, Wenisch C, Poglitsch M, Oberbauer R, Zoufaly A and Hecking M (2022) The systemic renin-angiotensin system in COVID-19, Scientific Reports, 10.1038/s41598-022-24628-1, 12:1 Lennol M, García-Ayllón M, Esteban M, García-Arriaza J and Sáez-Valero J (2022) Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy, Frontiers in Immunology, 10.3389/fimmu.2022.1001951, 13 Mariappan V, Ranganadin P, Shanmugam L, Rao S and Balakrishna Pillai A (2022) Early shedding of membrane-bounded ACE2 could be an indicator for disease severity in SARS-CoV-2, Biochimie, 10.1016/j.biochi.2022.06.005, 201, (139-147), Online publication date: 1-Oct-2022. Briand F, Sencio V, Robil C, Heumel S, Deruyter L, Machelart A, Barthelemy J, Bogard G, Hoffmann E, Infanti F, Domenig O, Chabrat A, Richard V, Prévot V, Nogueiras R, Wolowczuk I, Pinet F, Sulpice T and Trottein F (2022) Diet-Induced Obesity and NASH Impair Disease Recovery in SARS-CoV-2-Infected Golden Hamsters, Viruses, 10.3390/v14092067, 14:9, (2067) Norambuena-Soto I, Lopez-Crisosto C, Martinez-Bilbao J, Hernandez-Fuentes C, Parra V, Lavandero S and Chiong M (2022) Angiotensin-(1–9) in hypertension, Biochemical Pharmacology, 10.1016/j.bcp.2022.115183, 203, (115183), Online publication date: 1-Sep-2022. Carpenter R, Young M, Petri W, Lyons G, Gilchrist C, Carey R, Petri W and Bouvier N (2022) Repressed Ang 1–7 in COVID-19 Is Inversely Associated with Inflammation and Coagulation, mSphere, 10.1128/msphere.00220-22, 7:4, Online publication date: 31-Aug-2022. Silva M, Corradi G, Pérez Duhalde J, Nuñez M, Cela E, Gonzales Maglio D, Brizzio A, Salazar M, Espeche W and Gironacci M (2022) Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19, Biomedicine & Pharmacotherapy, 10.1016/j.biopha.2022.113201, 152, (113201), Online publication date: 1-Aug-2022. Tashchuk V and Khrebtii H (2022) Лікування артеріальної гіпертензії на сучасному етапі розвитку медичної практики, HYPERTENSION, 10.22141/2224-1485.15.1.2022.338, 15:1-2, (8-15) Savedchuk S, Raslan R, Nystrom S and Sparks M (2022) Emerging Viral Infections and the Potential Impact on Hypertension, Cardiovascular Disease, and Kidney Disease, Circulation Research, 130:10, (1618-1641), Online publication date: 13-May-2022. Quarleri J and Delpino M (2022) SARS-CoV-2 interacts with renin-angiotensin system: impact on the central nervous system in elderly patients, GeroScience, 10.1007/s11357-022-00528-0, 44:2, (547-565), Online publication date: 1-Apr-2022. Akin S, Schriek P, van Nieuwkoop C, Neuman R, Meynaar I, van Helden E, Bouazzaoui H, Baak R, Veuger M, Mairuhu R, van den Berg L, van Driel V, Visser L, de Jonge E, Garrelds I, Duynstee J, van Rooden J, Ludikhuize J, Verdonk K, Caliskan K, Jansen T, van Schaik R and Danser A (2021) A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity, Journal of Hypertension, 10.1097/HJH.0000000000003054, 40:3, (606-614), Online publication date: 1-Mar-2022. Fagyas M, Fejes Z, Sütő R, Nagy Z, Székely B, Pócsi M, Ivády G, Bíró E, Bekő G, Nagy A, Kerekes G, Szentkereszty Z, Papp Z, Tóth A, Kappelmayer J and Nagy B (2022) Circulating ACE2 activity predicts mortality and disease severity in hospitalized COVID-19 patients, International Journal of Infectious Diseases, 10.1016/j.ijid.2021.11.028, 115, (8-16), Online publication date: 1-Feb-2022. Xu C, Chen Y and Yu J (2021) Foe and friend in the COVID-19-associated acute kidney injury: an insight on intrarenal renin-angiotensin system, Acta Biochimica et Biophysica Sinica, 10.3724/abbs.2021002, 54:1, (1-11), Online publication date: 1-Jan-2022. Al Ghorani H, Götzinger F, Böhm M and Mahfoud F (2022) Arterial hypertension – Clinical trials update 2021, Nutrition, Metabolism and Cardiovascular Diseases, 10.1016/j.numecd.2021.09.007, 32:1, (21-31), Online publication date: 1-Jan-2022. Ozkan S and Ipekci A (2022) Serum Angiotensin II as a Biomarker in COVID-19 Biomarkers in Trauma, Injury and Critical Care, 10.1007/978-3-030-87302-8_69-1, (1-24), . Biberoğlu S, İpekci A, İkizceli İ, Çakmak F, Akdeniz Y, Kanbakan A, Konukoğlu D, Bolayırlı İ, Börekçi Ş, Ürkmez S and Özkan S (2021) Role of plasma angiotensin II and angiotensin-converting enzyme 2 levels on prognosis and mortality in hypertensive patients with COVID-19, Biomarkers in Medicine, 10.2217/bmm-2021-0121, 15:17, (1581-1588), Online publication date: 1-Dec-2021. Dominiczak A and Meyer T (2021) Hypertension Update: A Reflection of the Past Decade, Hypertension, 78:6, (1670-1673), Online publication date: 1-Dec-2021. Natarelli L, Virgili F and Weber C (2021) SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad, International Journal of Molecular Sciences, 10.3390/ijms222212243, 22:22, (12243) Enners S, Gradl G, Kieble M, Böhm M, Laufs U and Schulz M (2021) Utilization of drugs with reports on potential efficacy or harm on COVID ‐19 before, during, and after the first pandemic wave , Pharmacoepidemiology and Drug Safety, 10.1002/pds.5324, 30:11, (1493-1503), Online publication date: 1-Nov-2021. de Ligt M, Hesselink M, Jorgensen J, Jocken J, Blaak E and Goossens G (2021) The angiotensin II type 1 receptor blocker valsartan in the battle against COVID‐19, Obesity, 10.1002/oby.23221, 29:9, (1423-1426), Online publication date: 1-Sep-2021. García‐Ayllón M, Moreno‐Pérez O, García‐Arriaza J, Ramos‐Rincón J, Cortés‐Gómez M, Brinkmalm G, Andrés M, León‐Ramírez J, Boix V, Gil J, Zetterberg H, Esteban M, Merino E and Sáez‐Valero J (2021) Plasma ACE2 species are differentially altered in COVID‐19 patients, The FASEB Journal, 10.1096/fj.202100051R, 35:8, Online publication date: 1-Aug-2021. Valle Martins A, da Silva F, Bolais-Ramos L, de Oliveira G, Ribeiro R, Pereira D, Annoni F, Diniz M, Silva T, Zivianni B, Cardoso A, Martins J, Motta-Santos D, Campagnole-Santos M, Taccone F, Verano-Braga T and Santos R (2021) Increased circulating levels of angiotensin-(1–7) in severely ill COVID-19 patients, ERJ Open Research, 10.1183/23120541.00114-2021, 7:3, (00114-2021), Online publication date: 1-Jul-2021. Gonzalez S, Siddik A and Su R (2021) Regulated Intramembrane Proteolysis of ACE2: A Potential Mechanism Contributing to COVID-19 Pathogenesis?, Frontiers in Immunology, 10.3389/fimmu.2021.612807, 12 Kragstrup T, Singh H, Grundberg I, Nielsen A, Rivellese F, Mehta A, Goldberg M, Filbin M, Qvist P, Bibby B and Bader M (2021) Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients, PLOS ONE, 10.1371/journal.pone.0252799, 16:6, (e0252799) Miličić Stanić B, Maddox S, de Souza A, Wu X, Mehranfard D, Ji H, Speth R and Sandberg K (2021) Male bias in ACE2 basic science research: missed opportunity for discovery in the time of COVID-19, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 10.1152/ajpregu.00356.2020, 320:6, (R925-R937), Online publication date: 1-Jun-2021. Trump S, Lukassen S, Anker M, Chua R, Liebig J, Thürmann L, Corman V, Binder M, Loske J, Klasa C, Krieger T, Hennig B, Messingschlager M, Pott F, Kazmierski J, Twardziok S, Albrecht J, Eils J, Hadzibegovic S, Lena A, Heidecker B, Bürgel T, Steinfeldt J, Goffinet C, Kurth F, Witzenrath M, Völker M, Müller S, Liebert U, Ishaque N, Kaderali L, Sander L, Drosten C, Laudi S, Eils R, Conrad C, Landmesser U and Lehmann I (2020) Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19, Nature Biotechnology, 10.1038/s41587-020-00796-1, 39:6, (705-716), Online publication date: 1-Jun-2021. Oz M, Lorke D and Kabbani N (2021) A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2020.107750, 221, (107750), Online publication date: 1-May-2021. Savoia C, Volpe M and Kreutz R (2021) Hypertension, a Moving Target in COVID-19, Circulation Research, 128:7, (1062-1079), Online publication date: 2-Apr-2021. Wenzel U and Kintscher U (2020) ACE2 and SARS-CoV-2: Tissue or Plasma, Good or Bad?, American Journal of Hypertension, 10.1093/ajh/hpaa175, 34:3, (274-277), Online publication date: 2-Apr-2021. Rieder M, Wirth L, Pollmeier L, Jeserich M, Goller I, Baldus N, Schmid B, Busch H, Hofmann M, Kern W, Bode C, Duerschmied D and Lother A (2020) Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19, American Journal of Hypertension, 10.1093/ajh/hpaa169, 34:3, (278-281), Online publication date: 2-Apr-2021. Oz M and Lorke D (2021) Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury, Biomedicine & Pharmacotherapy, 10.1016/j.biopha.2020.111193, 136, (111193), Online publication date: 1-Apr-2021. Cohen J, South A, Shaltout H, Sinclair M and Sparks M (2021) Renin–angiotensin system blockade in the COVID-19 pandemic, Clinical Kidney Journal, 10.1093/ckj/sfab026, 14:Supplement_1, (i48-i59), Online publication date: 26-Mar-2021. Saravi B, Li Z, Lang C, Schmid B, Lang F, Grad S, Alini M, Richards R, Schmal H, Südkamp N and Lang G (2021) The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?, Cells, 10.3390/cells10030650, 10:3, (650) Kintscher U and Wenzel U (2021) ACE2, SARS-CoV-2 und RAAS-Blocker, CardioVasc, 10.1007/s15027-021-3471-y, 21:2, (25-27), Online publication date: 1-Mar-2021. Mahfoud F, Böhm M, Dörr O, Halbach M and Kintscher U (2021) Arterielle Hypertonie – Was war 2020 wichtig?Arterial hypertension—What was important in 2020?, Der Kardiologe, 10.1007/s12181-021-00470-z, 15:2, (127-132), Online publication date: 1-Mar-2021. Kurbel S (2020) The renin‐angiotensin system in COVID‐19: Why ACE2 targeting by coronaviruses produces higher mortality in elderly hypertensive patients?, BioEssays, 10.1002/bies.202000112, 43:3, Online publication date: 1-Mar-2021. Peng Y, Tao H, Satyanarayanan S, Jin K and Su H (2021) A Comprehensive Summary of the Knowledge on COVID-19 Treatment, Aging and disease, 10.14336/AD.2020.1124, 12:1, (155), . Steckelings U and Sumners C (2020) Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists, Clinical Science, 10.1042/CS20200922, 134:22, (2987-3006), Online publication date: 27-Nov-2020. Meyer R and Eckert N (2020) SARS-CoV-2: RAAS-Inhibitoren sind bei COVID-19 unproblematisch, Deutsches Ärzteblatt Online, 10.3238/PersKardio.2020.10.09.03 November 2020Vol 76, Issue 5 Advertisement Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/HYPERTENSIONAHA.120.15841PMID: 32851897 Originally publishedAugust 27, 2020 PDF download Advertisement SubjectsACE/Angiotensin Receptors/Renin Angiotensin SystemBiomarkersClinical StudiesPharmacology
Referência(s)